Nav: Home

Every atom counts

August 04, 2016

Malignant cancer cells not only proliferate faster than most healthy cells in our bodies. They also generate more "junk", such as faulty and damaged proteins. This makes cancer cells inherently more dependent on the most important cellular garbage disposal unit, the proteasome, which degrades defective proteins and removes them from circulation. Treatments for some types of cancer, such as multiple myeloma -- a type of bone marrow cancer -- exploit this dependence. Patients are treated with inhibitors, which selectively block the proteasome. The ensuing pile-up of cellular junk overwhelms the cancer cell, ultimately killing it. A team of researchers from Göttingen and Hamburg have now succeeded in determining the 3D structure of the human proteasome in unprecedented detail and have deciphered the exact mechanism by which inhibitors block the proteasome. Their surprising results, published today in Science, will pave the way to develop more effective proteasome inhibitors for cancer therapy.

In order to understand how cellular machines such as the proteasome work, it is essential to determine their three-dimensional structure in detail. With its more than 50.000 atoms, the barrel-shaped proteasome, however, is a true challenge for structural biologists. A group of scientists led by Ashwin Chari at the Max Planck Institute (MPI) for Biophysical Chemistry in Göttingen and Gleb Bourenkov at EMBL have now managed to determine the three-dimensional structure of the human proteasome at an unprecedented resolution of 1.8 Ångström -- enabling them to pinpoint the position of single atoms in the garbage disposal unit.

In a next step, the researchers solved the structure of the proteasome bound to four different inhibitors that are either already used in the clinic or are currently undergoing clinical trials. "The substantial improvement in resolution compared to previous proteasome structures has allowed us to establish the exact chemical mechanism by which inhibitors block the proteasome. This knowledge makes it possible to optimize inhibitor design and efficacy -- since only inhibitors tailored to the proteasome shut it down completely," says Chari, project group leader in the Department of Structural Dynamics headed by Holger Stark at the MPI for Biophysical Chemistry.

The scientists discovered an important detail in the proteasome's active site. The active site is what enables the proteasome to degrade the cell's junk, and it is what the inhibitor drugs bind to in order to shut off that activity. In contrast to the common perception, a 7-ring structure is formed by the chemical reaction of inhibitor and proteasome active site, which contains an additional so-called methylene group. This has far-reaching consequences for the inhibitor's efficacy and chemical mechanism, the researchers explain. "Even though a methylene group just comprises one carbon atom and its two associated protons amidst the more than 50.000 atoms of the proteasome, it decisively influences which chemical features make the inhibitor most effective in blocking the proteasome," says Thomas Schneider, who leads a group at EMBL. "This has to be taken into account when developing new inhibitors and searching for new drug candidates," adds Holger Stark. The researchers have already filed a patent application for the chemical procedure to design such inhibitors. "Clinical applications are always preceded by knowledge about targets - therefore, the details, where every atom counts, make all the difference," Bourenkov states.

Huge effort reveals a small difference

The project's success is the result of fantastic teamwork, as Max Planck researcher Chari emphasizes: "A group of scientists, all experts in their respective fields, contributed their specialized knowledge, expertise, and complemented each other perfectly." Structural biologists, physicists, enzymologists, and biochemists of the MPI for Biophysical Chemistry, EMBL, and the University of Göttingen developed several innovative procedures.

To determine a molecule's structure using X-ray crystallography, scientists grow crystals of that molecule, then shine a powerful beam of X-ray light on the crystal. Based on how the X-rays scatter after hitting the crystal, researchers can deduce the molecule's 3D structure. Fabian Henneberg and Jil Schrader, junior scientists in Stark's department and first authors of the report now published in Science, used a new method to purify proteasomes and grow the high-quality crystals that made it possible to solve its 3D structure in such detail. The scientists have filed for a second patent application based on the purification and crystallization procedure employed in this work. "The pipeline we use to purify and crystallize the proteasome with and without inhibitors is also suitable to discover new proteasome inhibitors - in an industrial setting, screening several hundred compounds per week could be feasible," Chari predicts.

However, the crystals were only one element of the project's success. The second were the cutting-edge instruments developed by the EMBL research facility on the Deutsches Elektronen Synchrotron (DESY) campus in Hamburg. "The DESY light source generates X-rays of exceptional quality. With the help of powerful X-ray optics, we were able to tailor X-rays to perfectly suit the crystallized proteasome. Only this made it possible to determine the proteasome structure in unprecedented detail," concludes Bourenkov.
-end-
The X-ray optics used in this work were installed in DESY's PETRA III hall in 2015 thanks to funding from the German Federal Ministry for Education and Research´s (BMBF) RÅC support scheme.

European Molecular Biology Laboratory

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...